G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz,Heinz Tüchler,Francesc Solé,Mar Mallo,E. Luño,José Cervera,Isabel Granada,Barbara Hildebrandt,Marilyn L. Slovak,Kazuma Ohyashiki,Christian Steidl,Christa Fonatsch,Michael Pfeilstöcker,Thomas Nösslinger,Peter Valent,Aristoteles Giagounidis,Carlo Aul,Michael Lübbert,Reinhard Stauder,Otto Krieger,Guillermo Garcia-Manero,Stefan Faderl,Sherry Pierce,Michelle M. Le Beau,John M. Bennett,Peter L. Greenberg,Ulrich Germing,Detlef Haase +27 more
TL;DR: A new and comprehensive cytogenetic scoring system based on an international data collection of 2,902 patients with primary MDS and oligoblastic acute myeloid leukemia (AML) after MDS treated with supportive care only is proposed, providing clear prognostic classification in 91% of all patients.
Journal ArticleDOI
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Rafael Bejar,Kristen E. Stevenson,Bennett A. Caughey,Omar Abdel-Wahab,David P. Steensma,Naomi Galili,Azra Raza,Hagop M. Kantarjian,Ross L. Levine,Donna Neuberg,Guillermo Garcia-Manero,Benjamin L. Ebert +11 more
TL;DR: Combining the LR-PSS and EZH2 mutation status identifies 29% of patients with lower-risk MDS with a worse-than-expected prognosis, and these patients may benefit from earlier initiation of disease-modifying therapy.
Journal ArticleDOI
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Andres O. Soriano,H. Yang,Stefan Faderl,Zeev Estrov,Francis J. Giles,Farhad Ravandi,Jorge E. Cortes,William G. Wierda,Souzanne Ouzounian,Andres Quezada,Sherry Pierce,Elihu H. Estey,Jean Pierre J. Issa,Hagop M. Kantarjian,Guillermo Garcia-Manero +14 more
TL;DR: The combination studied is safe and has significant clinical activity and a significant decrease in global DNA methylation and induction of histone acetylation were achieved.
Journal ArticleDOI
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
Marcos de Lima,Sergio Giralt,Peter F. Thall,Leandro de Padua Silva,Roy B. Jones,Krishna V. Komanduri,Thomas Braun,Hoang Q. Nguyen,Richard E. Champlin,Guillermo Garcia-Manero +9 more
TL;DR: The authors hypothesized that low‐dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination.
Journal ArticleDOI
Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
Anwesha Dey,Dhaya Seshasayee,Rajkumar Noubade,Dorothy French,Jinfeng Liu,Mira S. Chaurushiya,Donald S. Kirkpatrick,Victoria Pham,Jennie R. Lill,Corey E. Bakalarski,Jiansheng Wu,Lilian Phu,Paula Katavolos,Lindsay M. LaFave,Omar Abdel-Wahab,Zora Modrusan,Somasekar Seshagiri,Ken C. Dong,Zhonghua Lin,Mercedesz Balazs,Rowena Suriben,Kim Newton,Sarah G. Hymowitz,Guillermo Garcia-Manero,Flavius Martin,Ross L. Levine,Vishva M. Dixit +26 more
TL;DR: It is shown that mouse Bap1 gene deletion is lethal during embryogenesis, but systemic or hematopoietic-restricted deletion in adults recapitulates features of human myelodysplastic syndrome (MDS), and Knockin mice expressing B AP1 with a 3xFlag tag revealed that BAP1 interacts with host cell factor–1, O-linked N-acetylglucosamine transferase (OGT), and the polycomb group proteins ASXL